Cancer impacts every life. Join a webinar honoring the many faces of cancer, where survivors share their stories through and beyond diagnosis—highlighting the challenges, resilience & hope of life after cancer. All are welcome: bit.ly/4dGjhmI #CancerSurvivor #NCSD

The future of cancer care starts with the exchange of knowledge. Members of the IGCS Scientific Program Committee gathered in Chicago to review and allocate scientific abstracts for the upcoming IGCS Annual Global Meeting—and took a moment to join the #Jump4June challenge. Every abstract selected represents new research, new ideas, and new opportunities to improve care for women affected by gynecologic cancers around the world. Today, we're jumping for uterine cancer awareness. Every day, we're working to advance the science that advances care. June is Uterine Cancer Awareness Month. Now in its fourth year, this global campaign was initiated by IGCS and IGCANetwork and is sustained by the people working every day to improve women's cancer care—clinicians, researchers, advocates, survivors, and supporters worldwide. Join the movement. #Jump4June #UCAM igcs.org/ucam Early registration rates for the IGCS Annual Global Meeting are in effect through June 30. This UCAM, make your plans to join us in Montreal! igcsmeeting.com #IGCS2026 #IGCSMontreal

Calling all early career researchers in gynecologic oncology. 📣 The IGCS Early Career Network, in partnership with GCIG, is now accepting proposals for pragmatic trials aimed at improving outcomes for women with gynecologic cancers. Don't miss this opportunity to turn your innovative ideas into impactful, globally scalable research. 🚨Deadline: July 13🚨 🔗igcs.org/ecn-gcig/

🚨Uterine cancer now accounts for more gynecologic cancer deaths than any other gynecologic malignancy in the U.S., with over 68,000 new cases and 14,450 deaths projected for 2026. ‼️Incidence and mortality rates continue to rise. ✅Early recognition of symptoms — including abnormal uterine bleeding and pelvic pain — remains critical to improving outcomes. Screening, timely referral, and patient education save lives. #GynecologicOncology #EndometrialCancer #UterineCancer #WomensHealth #SGO2026

So privileged to serve as study chair for this first pragmatic and streamlined phase 3 trial in #ovariancancer looking to de-escalate PARPi maintenance. Thanks to all our patients and sites for participating. Let’s keep the momentum going! @NRGonc @TeamOvary_MSK @MSKCancerCenter

A big jump for awareness. A bigger commitment to progress. Thank you to GOG Foundation, a proud supporter of Uterine Cancer Awareness Month, for joining the #Jump4June challenge and helping advance the research that is transforming uterine cancer care. From clinical trials to precision medicine, today's discoveries are creating better options and brighter futures for patients around the world. Let's keep the momentum going. #Jump4June #UCAM @GOG @IGCANetwork @rcoledude

The STAMP trial (EA6174) is the largest clinical study (sponsored by @theNCI @eaonc) evaluating immunotherapy as an adjuvant treatment for Merkel cell carcinoma (MCC) after surgery. Hear @JaniceM10 describe the findings presented at #ASCO26 @Perlmutter_CC @nyulangone @nyugrossman

June is #UterineCancer Awareness Month. Uterine cancer incidence is rising, making early recognition, evidence-based care, and patient education more important than ever. This month, SGO is sharing resources to help clinicians support patients and improve outcomes. #GynOnc #UCAM

To watch this ASCO Interview with Dr. Barlin, click link in bio or go to ow.ly/6oq150Z6KGe. #gynecologiccancer @clinicaltrials #ovariancancer #ASCO26

Here is @ElaineShumMD on some of her outstanding work in lung cancer she is presenting at #ASCO26 @nyulangone @nyugrossman @Perlmutter_CC @Aiims1742

Really excited for the @IGCSociety meeting in Montreal in October- don’t miss this wonderful scientific program! Register now- looking forward to seeing everyone. @SGO_org @ASCO @myESMO @GOG

Great program!

🚨New podcast alert: @SGO_org's review of PARP inhibitors in ovarian cancer. Where we are after the FDA pulled back, what the EMA kept, and why BRCA/HRD status matters more than ever for patient selection. Listen read 👇gynecologiconcology-online.n…

Amazing day for pts #endometrialcancer. Both PFS and OS trial endpoints met- first ph 3 trial data for ADC in EC and TROP2 ADC data in GYN cancer! 🎉 @sgo.org @gogf @igcs @gyncsm @asco linkedin.com/posts/bhavana-p…

Today, SGO members and staff are on #CapitolHill moving the message at #SGOAdvocacyDay. We’re advocating for #gynecologiccancer research funding, improved patient access to care, and stronger education and awareness efforts nationwide. Stay tuned for our full recap. 🔬💙

An honor to meet with one of my heroes in biotech - the mercurial @kiranshaw! Thank you for visiting @Perlmutter_CC @nyulangone today.

Congrats @BredellaMD! This is great news!

🏆 We are so excited to congratulate lead author (and Gynecologic Oncology Reports Deputy Editor) Jamie Bakkum-Gamez on the @acog Foundation Innovation in #obgyn Award for her work detecting #endometrialcancer from self-collected vaginal fluid via tampon among people experiencing abnormal uterine bleeding. 🩸The article Is published in the May 2026 issue of gynecologic oncology and was selected Editor’s Choice Article. “Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleeding” 👀 Stay tuned for the #podcast drop in the next weeks! #gynecologiconcology

Watch our recent #PatientEducation webinar series to learn about cancer #ClinicalTrials, including phases, safety, risks vs benefits & more —while addressing common myths and questions from patients. Pt 1: youtu.be/PR342rdBa9E Pt 2: youtu.be/Bt3CIgmbSpE #CancerResearch

News from the @US_FDA for patients with metastatic #PancreaticCancer while the inevitable approval is happening for Daraxonrasib. nytimes.com/2026/05/01/busin…